Conference abstractPublished 15 Apr 2013
Subconjunctival bevacizumab injection in treatment of recurrent pterygium
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: To determine the clinical effect of subconjunctival injection of bevacizumab in regression or halting growth in patients with recurrent pterygium. Method and materials: The study was an off-label; 2-dosing, interventional case series involving 20 patients with recurrent pterygium. They received subconjunctival bevacizumab (0.2ml/ 2.5mg). vascularity and thickness of Pterygium was graded. size of the pterygium (measured by surface area in cm2) was recorded from baseline to 6 months, after injection. Treatment-related complications and adverse events were reported. The main outcome of measurements was the change in grading, size, vascularity, thickness and color intensity. Results: 9 males (45%), 11 females (55%) of 20 patients were conducted in study with a mean age of 50.46 years±18.30 (rang 38-70). There was a significant reduction in grading with significant difference in the mean surface area of pterygium at different intervals (P < 0.05) and the size of pterygium was reduced. The reduction of color intensity was significant (P =0.031). No significant topical or systemic adverse reactions were recorded.
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Ophthalmology
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “Hussein Alhammami”
